Berthet S, Olivier P, Montastruc JL, Lapeyre-Mestre M. Drug safety of rosiglitazone and pioglitazone in France : a study using the French PharmacoVigilance database. BMC Clin Pharmacol 2011, 11, 5.

Bismuth M, Oustric S, Boyer P, Escourrou B, Brillac T, Mesthe P, Boutin A, Arlet P, Montastruc JL. La pharmacie familiale : enquête auprès d’un échantillon de patients en Midi-Pyrénées. Thérapie 2011, 66, 131-134.

Bismuth S, Laing-Leng E, Oustric S, Montastruc JL, Lapeyre-Mestre M. Quels antalgiques après le retrait du dextropropoxyphène ? Enquête auprès de médecins généralistes de la région Midi-Pyrénées. Thérapie 2011, 66, 25-28.

Bœuf-Cazou O, Lapeyre-Mestre M, Niezborala M, Montastruc JL. Profil de consommation de substances psychoactives dans le milieu du travail : résultats de l’enquête "mode de vie et travail". Thérapie 2011, 66, 155-165.

Bondon-Guitton E, Perez-Lloret S, Bagheri H, Brefel C, Rascol O, Montastruc JL. Drug-induced parkinsonism : a review of 17 years experience in a regional pharmacovigilance center in France. Mov Disord 2011, 12, 2226-31.

Bondon-Guitton E, Prévot G, Didier A, Montastruc JL. Pulmonary arterial hypertension and benfluorex : 5 case reports. Thérapie 2011, 66, 135-136.

Caillet C, Durrieu G, Jacquet A, Faucher A, Ouaret S, Perrault-Pochat MC, Kreft-jais C, Castot A, Montastruc JL and French Network of PharmacoVigilance Centres (CRPV) : Autret-Leca E, Baldin B, Bavoux F, Bénard-laribière A, Biour M, Beyens MN, Colin F, Coquerel A, Crepin S, Décréau-Gaillon G, Dos Santos S, Efthekhari P, Favrelière S, Gautier S, Gras-Champel V, Javot L, Jean-Pastor MJ, Le Beller C, Lebrun-Vignes B, Millaret A, Perrazi A, Pinzani V, Riché C, Schir E, Sgro C, Tebacher-Alt M, Trenque T, Valnet-Rabier MB, Veyrac G . Safety surveillance of influenza A(H1N1)v monovalent vaccines during the 2009-2010 mass vaccination campaign in France. Eur J Clin Pharmacol 2011, 67, 649-651.

Crespin S, Bourrel R, Hurault-Delarue C, Lapeyre-Mestre M, Montastruc JL, Damase-Michel C. Drug prescribing before and during pregnancy in south west France. Drug Saf 2011, 34, 595-604.

Dieleman J, Romio S, Johansen K, Weibel D, Bonhoeffer J, Sturkenboom M. Guillain-Barré syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine : multinational case-control study in Europe. Br Med J 2011,343, d3908.

Droz-Perroteau C, Dureau-Pournin C, Vespignani H, Marchal C, Blin P, Blazejewski S, Pollet C, Jové J, Robinson P, Moore N, Fourrier-Réglat A, on behalf of the EULEV study group (Vespignani H, Marchal C, Alpérovitch A, Bénichou J, Jager A, Lavernhe G, Mann M, Montastruc JL, Pédespan JM). The EULEV cohort study : rates of and factors associated with continuation of levetiracetam after 1 year. Br J Clin Pharmacol 2011, 1, 121-7.

Duhalde V, Delarue C, Lacroix I, Suarez C, Bourrel R, Montastruc JL, Damase-Michel C. Antihypertensive drug prescription pattern before and during pregnancy in France. Pregnancy hypertension : An International Journal of Women’s Cardiovascular Health 2011, 185-189.

Durrieu G, Caillet C, Lacroix I, Jacquet A, Faucher A, Ouaret S, Sommet A, Perault-Pochat MC, Kreft-Jais C, Castot A, Damase-Michel C, Montastruc JL, et le Réseau Français des centres de pharmacovigilance. Campagne nationale de vaccination contre la grippe A (H1N1)v : suivi national de pharmacovigilance. Thérapie 2011, 66, 527-40.

Fuzier R, Bataille B, Fuzier V, Richez AS, Maguès JP, Choquet O, Montastruc JL, Lapeyre-Mestre M. Spinal anesthesia failure after local anesthetic injection into cerebrospinal fluid. Regional Anesth and Pain Med 2011, 36, 322-26.

Grossac J, Ruiz S, Bondon-Guitton E, Roux FE, Fourcade O, Montastruc JL, Geeraerts T. Severe intracranial bleeding related to vitamin K Antagonist-Ropinirole interaction. Mov Disord. 2011, 26, 1962-63.

Hillaire-Buys D, Faillie JL, Montastruc JL. Pioglitazone and bladder cancer. Lancet 2011, 378, 1543-4.

Hurault-Delarue C, Lacroix I, Vidal S, Montastruc JL, Damase-Michel C. Drugs in pregnancy : study in the EFEMERIS database (2004 to 2008). Gynecol Obstet Fertil 2011, 10, 554-8.

Jegu J, Gallini A, Soler P, Montastruc JL, Lapeyre-Mestre M. Slow-release oral morphine for opioid maintenance treatment : a systematic review. Br J Clin Pharmacol 2011, 71, 832-843.

Lacroix I, Berrebi A, Garipuy D, Schmitt L, Hammou Y, Chaumerliac C, Lapeyre-Mestre M, Montastruc JL, Damase-Michel C. Buprenorphine versus methadone in pregnant opioid-dependent women : a prospective multicenter study. Eur J Clin Pharmacol. 2011, 67, 1053-59.

Lacroix I, Damase-Michel C, Kreft-Jais C, Castot A, Montastruc JL. 2009 H1N1 influenza vaccines in pregnant women : the French Pharmacovigilance survey. Vaccine 2011, 7, 1357-8.

Lacroix I, Hurault-Delarue C, Kessler S, Guitard C, Vidal S, Albouy-Cossard C, Montastruc JL, Damase-Michel C. First epidemiologic data about phloroglucinol exposure during first trimester of pregnancy. Gynecol Obstet Fertil 2011, 39, 694-697.

Lucena MI, Molokhia M, Shen Y, Urban TJ, Aithal GP, Andrade RJ, Day CP, Ruiz-Cabello F, Donaldson PT, Stephens C, Mirmohamde M, Romero-Gomez M, Navarro JM, Fontana RJ, Miller M, Groome M, Bondon-Guitton E, Conforti A, Stricker BHC, Carvajal A, Ibanez L, Yue QY, Eichelbaum M, Floratos A, Pe’er I, Daly MJ, Goldstein DB, Dillon JF, Nelson MR, Watkins PB, Daly AK for the Spanish DILI Registry, EUDRAGENE, DILIN, DILIGEN, and international SAEC. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 2011, 141, 338-47.

Montastruc JL, Durrieu G, Rascol O. Pandemrix°, (H1N1)v influenza and reported cases of narcolepsy. Vaccine 2011, 29, 2011.

Montastruc JL, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and Strengths of the disproportionality analysis for identification of Adverse Drug Reactions in a PharmacoVigilance database. Br J Clin Pharmacol. 2011, 72, 905-908.

Noize P, Bagheri H, Durrieu G, Haramburu F, Moore N, Giraud P, Galinier M, Pourrat J, Montastruc JL. Life-threatening drug-associated hyperkalemia : a retrospective study from laboratory signals. Pharmacoepidemiol Drug Saf 2011, 20,747-753.

Omon E, Damase-Michel C, Hurault-Delarue C, Lacroix I, Montastruc JL, Oustric S, Escourrou B. Non-adjuvanted 2009 influenza A (H1N1)v vaccine pregnant women : the results of a French prospective descriptive study. Vaccine 2011, 29, 9649-54.

Orriols L, Philip P, Moore N, Castot A, Gadegbeku B, Delorme B, Mallaret M, Lagarde E ; on behalf of the CESIR Research Group : Avalos M, Bazin F, Blazejewski S, Contrand B, Durrieu G, Girodet PO, Goldberg M, Laumon B, Lauque D, Lecoules N, Memes L, Merle L, Merlière Y, Montastruc JL, Noize P, Orsoni N, POariente A, Ribéreau-Gayon R, Salmi LR, Thiessard F, Tricotel A. Benzodiazepine-like hypnotics and the associated risk of road traffic accidents. Clin Pharmacol Ther 2011, 89, 595-601.

Perrin-Terrin A, Pathak A, Lapeyre-Mestre M. QT interval prolongation : prevalence, risk factors and pharmacovigilance data among methadone-treated patients in France. Fundam Clin Pharmacol. 2011 Aug ;25(4):503-10.

Rouve N, Bagheri H, Telmon N, Pathak A, Franchitto N, Schmitt L, Rougé D, Lapeyre-Mestre M, Montastruc JL ; the French Association of Regional PharmacoVigilance Centres. Prescribed drugs and violence : a case/noncase study in the French PharmacoVigilance Database. Eur J Clin Pharmacol. 2011, 67, 1189-98.

Salmon-Ceron D, Tubach F, Lortholary O, Chosidow O, Bretagne S, Nicolas N, Cuillerier E, Fautrel B, Michelet C, Morel J, Puechal X, Wendling D, Lemann M, Ravaud P, Mariette X, Bagheri H, Blandin B, Breban M, Bretagne S, Castot A, Chichmanian RM, Chosidow O, Dautzenberg B, Dellamonica P, Dufeu-Demazes N, Emilie D, Gillet C, Hugot JP,Kreft Jais C, Leport C, Montastruc JL, Prieur AM, Ravaud P, Roux C, Vittecoq D. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective french RATIO registry. Ann Rheum Dis 2011, 70, 616.

Wagner S, Varet-Legros M, Fabre C, Montastruc JL, Bagheri H. Confounding factors for variation of clozapine plasma levels : drug interactions with proton pump inhibitor or infectious aetiologies ? Eur J Clin Pharmacol 2011, 67, 533-534.

Avalos M, Adroher ND, Lagarde E, Thiessard F, Grandvalet Y, Contrand B, Oriols L, Montastruc JL, CESIR Research Group. Prescription-Drug-Related risk in driving : comparing conventional and lasso shrinkage logistic regressions. Epidemiology 2012, 23, 706-12.

Berard A, Sheehy O, Damase-Michel C, Crespin S. Paroxetine use during pregnancy and perinatal outcomes including types of cardiac malformations in Quebec and France : a short communication. Curr Drug Saf. 2012, 7, 207-10.

Bernard N, Joinville-Bera AP, Carlier P, Boyer M, Damase-Michel C, Vial T, Descotes J. Pregnancy outcomes after in uteroexposure to baclofen. Reproductive Toxicology 2012, 34, 155-73.

Bibas N, Sartor V, Bulai Livideanu C, Bagheri H, Nougué J, Giordano-Labadie F, Maza A, Paul C, Chouini-Lalanne N, Marguery MC. Contact photoallergy to isopenthipendyl chlorhydrate. Dermatology 2012, 4, 289-91.

Blazejewski S, Girodet PO, Orriols L, Capelli A, Moore N, Montastruc JL, CESIR Group. Factors associated with serious traffic crashes : a prospective study in southwest France. Arch Intern Med 2012, 172, 1039-41.

Bondon-Guitton E, Bagheri H, Montastruc JL and The French Network of Regional PharmacoVigilance Centers. Drug-induced gingival overgrowth : a study in the French Pharmacovigilance Database. J Clin Periodontol 2012, 39, 513-518.

Bordenave H, Despas F, Sommet A, Montastruc JL. Patient’s Medicine Cabinet Composition Study of 207 Families in France. Therapie 2012, 67, 137-43

Bounhoure JP, Montastruc JL. Risque hémorragique et syndromes coronariens aigus chez les sujets âgés. Bull Acad Natle Méd 2011, 195, 1981-1987.

Braillon A, Bewley S, Herxheimer A, Mansfield P, Lexchin J, Menkes DB, Ziganshina LE, Montastruc JL. Marketing versus evidence-based medicine. Lancet 2012, 380, 340.

Caillet C, Moachon L, Montastruc JL, Bagheri H, French Association of Regional Pharmacovigilance Centers. Safety profile of enantiomers versus racemic mixture : it’s the same ? Br J Clin Pharmacol 2012, 74, 886-89.

Chaveron D, Silva S, Sanchez-Verlaan P, Conil JM, Sommet A, Geeraerts T, Génestal M, Minville V, Fourcade O. The 90 % effective dose of a sufentanil bolus for the management of painful positioning in intubated patients in the ICU. Eur J Anaesthesiol 2012, 29, 280-285.

Durrieu G, Palmaro A, Pourcel L, Caillet C, Faucher A, Jacquet A, Ouaret S, Perault-Pochat MC, Kreft-Jais C, Castot A, Lapeyre-Mestre M, Montastruc JL. First french experience of ADR reporting by patients after a mass immunization campaign with influenza A (H1N1) pandemic vaccines. Drug Saf 2012, 35, 845-854.

Ferrie B, Dupouy J, Lassoued S, Oustric S, Durrieu G, Rouge-Bugat ME, Montastruc JL. Myopathie sévère par intoxication à la colchicine : à propos d’un cas. Thérapie 2012, 67, 482-3.

Fournier JP, Lapeyre-Mestre M, Sommet A, Dupouy J, Poutrain JC, Montastruc JL. Laboratory monitoring of patients treated with antihypertensive therapy and newly exposed to non steroidal anti-inflammatory drugs. PLoS One 2012, 7, 3, e34187.

Fournier JP, Sommet A, Bourrel R, Oustric S, Pathak A, Lapeyre-Mestre M, Montastruc JL. Non-steroidal anti-inflammatory drugs (NSAIDs) and hypertension treatment intensification : a population-based cohort study. Eur J Clin Pharmacol 2012, 68, 1533-40.

Gardette V, Lapeyre-Mestre M, Coley N, Cantet C, Montastruc JL, Vellas B, Andrieu S. Antipsychotic use and mortality risk in community-dwelling Alzheimer’s disease patients : evidence for a role of dementia severity. Curr Alzheimer Res 2012, 9, 1106-1116.

Gass-Jégu F, Damase-Michel C, Hurault-Delarue C, Bourrel R, Montastruc JL. Analysis of Prescriptions associated to Hormone Replacement Therapy in Midi-Pyrénées Region. Therapie 2012, 67, 121-8.

Herxheimer A, Vohra S, Montastruc JL, Edwards R. A major rethink is needed on reporting adverse drug reactions. Br Med J 2012, 345, e6379.

Hillaire-Buys D, Faillie JL, Montastruc JL, Petit P. Stay vigilant : a glitazone (pioglitazone) can hide a glitazar !. Eur J Clin Pharmacol 2012, 68, 1681-83.

Jacquot J, Gony M, Baudrin D, Chastel X, Montastruc JL, Bagheri H. Could we Improve Notification of Adverse Drugs Reactions in Hospital ? Assessment of 5 Years of Network PharmacoMIP’s Activities. Therapie 2012, 67, 231-6.

Jouanjus E, Pourcel L, Saivin S, Molinier L, Lapeyre-Mestre M.  Use of multiple sources and capture-recapure method to estimate the frequency of hospitalization related to drug abuse. Pharmacoepidemiol Drug Saf 2012, 21, 733-41.

Lacroix I, Hurault-Delarue C, Montastruc JL, Damase-Michel C. Can benfluorex induce congenital malformations ? Diabetes Metab 2012, 38, 373-4.

Lefort A, Arlet P, Bagheri H, Campistron E. Hypomagnésémie avec hypocalcémie sous oméprazole. Thérapie 2012, 67, 191-2.

Maschino F, Hurault-Delarue C, Chebbane L, Fabry V, Montastruc JL, Bagheri H ; French Association of Regional Pharmacovigilance Centers. Bleeding adverse drug reactions (ADRs) in patients exposed to antiplatelet plus serotonin reuptake inhibitor drugs : analysis of the French Spontaneous Reporting Database for a controversial ADR. Eur J Clin Pharmacol 2012, 68, 1557-60.

Montastruc F, Montastruc G, Vigreux P, Bruneval P, Guilbeau-Frugier C, Cron C, Bagheri H, Delisle B, Lapeyre-Mestre M, Pathak A, Montastruc JL. Valvular heart disease in a patient taking 3,4-methylenedioxymethamphetamine (MDMA, ’Ecstasy’). Br J Clin Pharmacol 2012, 74, 547-548.

Montastruc F, Schwarz N, Schmitt L, Bui E. An overview of the symptoms and typical disorders associated with Alice in wonderland syndrome. Neuropsychiatry 2012, 2, 281-9.

Montastruc F, Sommet A, Bondon-Guitton E, Durrieu G, Bui E, Bagheri H, Lapeyre-Mestre M, Schmitt L, Montastruc JL. The importance of drug-drug interactions as a cause of adverse drug reactions : a pharmacovigilance study of serotoninergic reuptake inhibitors in France. Eur J Clin Pharmacol 2012, 68, 767-775.

Moulis G, Batz A, Durrieu G, Viard C, Decramer S, Montastruc JL. Severe neonatal hypercalcemia related to maternal exposure to nutritional supplement containing Spirulina. Eur J Clin Pharmacol 2012, 68, 221-222.

Moulis G, Béné J, Sommet A, Sailler L, Lapeyre-Mestre M, Montastruc JL and The French Association of PharmacoVigilance Centres. Statin-induced lupus : a case/non-case study in a nationwide pharmacovigilance database. Lupus 2012, 21, 885-9.

Moulis G, Sailler L, Sommet A, Lapeyre-Mestre M, Montastruc JL and the French Association of Regional Pharmacovigilance Centers. Exposure to inhibitors of the renin-angiotensin system is a major independent risk factor for acute renal failure induced by sucrose-containing intravenous immunoglobulins : a case-control study. Pharmacoepidemiol Drug Saf 2012, 21, 314-319.

Moulis G, Sommet A, Durrieu G, Bagheri H, Lapeyre-Mestre M, Montastruc JL and The French Association of Pharmacovigilance centres. Trends of reporting of "serious" vs. "non serious" adverse drug reactions over time : a study in the French PharmacoVigilance database. Br J Clin Pharmacol 2012, 74, 201-204.

Moulis G, Sommet A, Sailler L, Lapeyre-Mestre M, Montastruc JL, The French Association Of Regional Pharmacovigilance Centers. Drug-induced immune thrombocytopenia : A descriptive survey in the French PharmacoVigilance database. Platelets 2012, 23,490-4.

Orriols L, Queinec R, Philip P, Gadegbeku B, Delorme B, Moore N, Suissa S, Lagarde E ; CESIR Research Group. Risk of injurious road traffic crash after prescription of antidepressants. J Clin Psychiatry 2012, 73, 1088-94.

Paludetto MN, Olivier-Abbal P, Montastruc JL. Is spontaneous reporting always the most important information supporting drug withdrawals for pharmacovigilance reasons in France ? Pharmacoepidemiol Drug Saf 2012, 21, 1289-94.

Perez-Lloret S, Rey MV, Bondon-Guitton E, Rascol O, Montastruc JL. Drugs associated with restless legs syndrome : a case/non case study in the French Pharmacovigilance database. J Clin Psychopharmacol 2012, 32, 827-7.

Perez-Lloret S, Rey MV, Fabre N, Ory F, Spampinato U, Brefel-Courbon C, Montastruc JL, Rascol O. Prevalence and Pharmacological factors associated with impulse-control disorders symptoms in patients with Parkinson disease. Clin Neuropharmacol 2012, 35, 261-5.

Perez-Lloret S, Rey MV, Fabre N, Ory F, Spampinato U, Montastruc JL, Rascol O. Do Parkinson’s disease patients disclose their adverse events spontaneously ? Eur J Clin Pharmacol 2012, 5, 857-65.

Perez-Lloret S, Rey MV, Fabre N, Ory F, Spampinato U, Senard JM, Pavy-Le Traon A, Montastruc JL, Rascol O. Factors related to orthostatic hypotension in Parkinson’s disease. Parkinsonism Relat Disord. 2012, 18, 501-5.

Roulet L, Asseray N, Foucher N, Potel G, Lapeyre-Mestre M, Ballereau F. Etude des comportements d’automédication chez les patients admis dans un service d’urgences médicales. Thérapie 2012, 67, 447-55.

Sommet A, Durrieu G, Lapeyre-Mestre M, Montastruc JL and The Association of French PharmacoVigilance Centres. A comparative study of adverse drug reactions during two heat waves that occurred in France in 2003 and 2006. Pharmacoepidemiol Drug Saf 2012, 21, 285-288.

Sommet A, Ferrières N, Jaoul V, Cadieux L, Soulat JM, Lapeyre-Mestre M, Montastruc JL. Use of drugs, tobacco, alcohol and illicit substances in a french student population. Thérapie 2012, 67, 429-35.

Stamenkovic S, Solesse A, Zanetti L, Zagury P, Vray M, et le groupe "Intérêt de santé publique et études post-inscription (ISPEP) Lapeyre-Mestre M. Guide de la Haute Autorité de Santé (HAS) : les études post inscription sur les technologies de santé (médicaments, dispositifs médicaux et actes) : principes et méthodes. Thérapie 2012, 67, 409-21.

Abadie D, Durrieu G, Roussin G, Montastruc JL. Effets indésirables "graves" du tramadol : bilan 2010-2011 de pharmacovigilance en France. Thérapie 2013, 68, 77-84.

Amar J, Lieber A, Montastruc F, Bagheri H, Pathak A, Montastruc JL. Arterial hypertension and resistance to antihypertensive treatment : a new adverse drug reaction with Modafinil. Therapie 2013, 68, 53-4.

Bezzina C, Bondon-Guitton E, Montastruc JL. Inhaled corticosteroid-induced hair depigmentation in a child. J Drugs Dermatol. 2013, 1, 119-20.

Castel M, Despas F, Modesto A, Gales C, Honton B, Galinier M, Senard JM, Pathak A. Cardiotoxicity of chemotherapies. Presse Med. 2013 Jan ;42(1):26-39. French.

Chavant F, Ingrand I, Jonville-Bera AP, Plazanet C, Gras-Champel V, Lagarce L, Zenut M, Disson-Dautriche A, Logerot S, Auffret M, Coubret-Dumas A, Bruel ML, Boyer M, Bos-Thompson MA, Veyrac G, Carlier P, Beyens MN, Lates S, Damase-Michel C, Castot A, Kreft-Jaus C, Pérault-Pochat MC. The PREGVAXGRIP study : a cohort study to assess foetal and neonatal consequences of in utero exposure to vaccination against A(H1N1)V2009 influenza. Drug saf 2013, 36,

Damase-Michel C, Hurault-Delarue C. Ibuprofen does not seem to increase global malformation risk but NSAID use in late pregnancy remains a concern. Evid Based Med doi:10.1136/eb-2013-101495

Danton AC, Montastruc F, Sommet A, Durrieu G, Bagheri H, Bondon-Guitton E, Lapeyre-Mestre M, Montastruc JL. Importance of cytochrome P450 (CYP450) in adverse drug reactions due to drug-drug interactions : a pharmacovigilance study in France. Eur J Clin Pharmacol 2013, 69,885-888.

Durrieu G, Mazau B, Jégu J, Lapeyre-Mestre M, Delord JP, Montastruc JL. Drugs and cancer : an analysis of the french pharmacoviiglance database. Thérapie 2013, 68, 149-54.

Faillie JL, Petit P, Montastruc JL, Hillaire-Buys D. Scientific evidence and controversies about pioglitazone and bladder cancer : which lessons can be drawn ? Drug Saf 2013, 36, 693-707.

Faye E, Bondon-Guitton E, Olivier-Abbal P, Montastruc JL, Spontaneous reporting of serious cutaneous reactions with protein kinase inhibitors. Eur J Clin Pharmacol 2013, 69, 1819-26.

Fuzier R, Serres I, Guitton E, Lapeyre-Mestre M, Montastruc JL ; French Network of Pharmacovigilance Centres. Adverse drug reactions to gabapentin and pregabalin : a review of the French pharmacovigilance database. Drug Saf 2013, 36, 55-62.

Gulmez SE, Larrey D, Pageaux GP, Lignot S, Lassalle R, Jové J, Gatta A, McCormick PA, Metselaar HJ, Monteiro E, Thorburn D, Bernal W, Zouboulis-Vafiadis I, de Vries C, Perez-Gutthann S, Sturkenboom M, Bénichou J, Montastruc JL, Horsmans Y, Salvo F, Hamoud F, Micon S, Droz-Perroteau C, Blin P, Moore N. Transplantation for acute liver failure in patients axposed to NSAIDs or paracetamol (Acetaminophen) : the multinational case-population SALT study. Drug Saf. 2013, 36, 135-44.

Gulmez SE, Moore N, Pageaux GP, Lignot S, Horsmans Y, Stricker B, Bernuau J, Bissoli F, Thorburn D, Montastruc JL, Micon S, Hamoud F, Lassalle R, Jové J, Blin P, Larrey D. Causality of Drugs Involved in Acute Liver Failure Leading to Transplantation : Results from the Study of Acute Liver Transplant (SALT). Drug Saf 2013, 36, 757-64.

Lapeyre-Mestre M, Grolleau S, Montastruc JL. Adverse drug reactions associated with the use of NSAIDS : a case/non case analysis of spontaneous reports from the french pharmacovigilance database 2002-2006. Fundam Clin Pharmacol 2013, 27, 223-230.

Laroche ML, Perault-Pochat MC, Ingrand I, Merle L, Kreft-Jais C, Casto-Villepelet A, Durrieu G, Gras V, Guy C, Jean-Pastor MJ, Jonville-Béra AP, Merlet-Chicoine I, Miremont-Salamé G, Nourashemi F, Charmes JP. Adverse drug reactions in patients with Alzheimer’s disease and related dementia in France : a national multicentre cross-sectional study. Pharmacoepidemiol Drug Saf 2013, 22, 952-60.

Le Lay M, Fournier JP, Montastruc JL. Interactions médicamenteuses potentielles en médecine générale : comparaison de deux études transversales en 1997 et 2012. Thérapie 2013, 68 , 411-3.

Mintzes B, Lexchin J, Sutherland JM, Beaulieu MD, Wilkes MS, Durrieu G, Reynolds E. Pharmaceutical sales representatives and patient safety : a comparative prospective study of information quality in Canada, France and the United States. J Gen Med Intern 2013 ; 28, 1368-75.

Montastruc F, Gardette V, Cantet C, Piau A, Lapeyre-Mestre M, Vellas B, Montastruc JL, Andrieu S. Potentially inappropriate medication use among patients with Alzheimer disease in the REALFR cohort : be aware of atropinic and benzodiazepine drugs ! Eur J Clin Pharmacol 2013, 69, 1589-97.

Montastruc F, Laffont M, Bagheri H, Montastruc JL. Potentially inappropriate medications in the elderly in France : a study in community pharmacies in 2011-2012. Eur J Clin Pharmacol 2013, 69, 741-2.

Montastruc F, Schmitt L, Montastruc JL, Pathak A. QT interval and antidepressant use : a cross sectional study of electronic health records. BMJ 2013 ;346:f288 doi : 10.1136/bmj.f288

Montastruc JL, Laffon de Mazières C, Montastruc F, Moulis G. Réflexions éthiques après l’affaire du Médiator°. Bioethique.com/index. 27 novembre 2013.

Moulis G, Sommet A, Béné J, Montastruc F, Sailler L, Montastruc JL, Lapeyre-Mestre M. Cancer risk on anti-TNF-a at recommended doses in adult rheumatoid arthritis : a meta-analysis with intention to treat and per protocol analyses. Plos One 2013, DOI : 10.1371.

Moulis G, Sommet A, Lapeyre-Mestre M, Montastruc JL. Is the risk of tumor necrosis factor inhibitor-induced lupus the same with monoclonal antibodies and soluble receptor ? A case/non case study in a nationwide pharmacovigilance database. Arthritis Rheum 2013, 65, 612-3.

Olivier-Abbal P, Teisseyre AC, Montastruc JL. Comparison of serious adverse reactions between thalidomide and lenalidomide : analysis in the French pharmacovigilance database. Med Oncol 2013, 30, 733.

Orriols L, Foubert-Samier A, Gadegbeku B, Delorme B, Tricotel A, Philip P, Moore N, Lagarde E, CESIR Research Group. Prescription of antiepileptics and the risk of road traffic crash. J Clin Pharmacol 2013, 53, 339-44.

Sommet A, Georgel B, Poutrain JC, Oustric S, Bourrel R, Montastruc JL, Birebent J. Différence de taux de substitution des médicaments génériques en Midi-Pyrénées en fonction des classes pharmaco-thérapeutiques. Rev Epidémiol Sant Pub 2013, 61, 539-44.

Abadie D, Chebane L, Bert M, Durrieu G, Montastruc JL. Online reporting of adverse drug reactions : a study from a french regional pharmacovigilance center. Thérapie. 2014 ;69:395-400.

Abadie D. Le syndrome sérotoninergique en pratique. In CD du 26e Forum de la Faculté de Médecine Toulouse Rangueil et Purpan le 26 octobre 2014.

Abou Taam M, Rossard C, Cantaloube L, Bouscaren N, Roche G, Pochard L, Montastruc F, Herxheimert A, Montastruc JL, Bagheri H. Analysis of patients narratives posted on social media websites on benfluorex’s (Mediator) withdrawal in France. J Clin Pharm Ther. 2014 ; 39:53-5.

Allavena C, Jacomet C, Pereira B, Morand-Joubert L, Bagheri H, Cotte L, Garaffo R, Gerbaud L, Dellamonica P. Acceptability and confidence in antiretroviral generics of physicians and HIV-infected patients in France. J Int AIDS Soc. 2014 ;17:19608.

Beau AB, Hurault-Delarue C, Vial T, Montastruc JL, Damase-Michel C, Lacroix I. Safety of oseltamivir during pregnancy : a comparative study using the EFEMERIS database. Br J Obst Genycol. 2014 ;121:895-900.

Beau AB, Hurault-Delarue C, Vidal S, Guitard C, Vayssière C, Petiot D, Montastruc JL, Damase-Michel C, Lacroix I. Pandemic A/H1N1 influenza vaccination during pregnancy : a comparative study using the EFEMERIS database. Vaccine. 2014 ;32:1254-8.

Bondon-Guitton E. Pharmacogénétique en pratique. In CD du 26e Forum de la Faculté de Médecine Toulouse Rangueil et Purpan le 26 octobre 2014.

Bouvenot G, Bounhoure JP, Monatstruc JL, Vacheron A. Rapport sur les anticoagulants oraux directs (AOD). Académie Nationale de Médecine. http://www.academie-medecine.fr/wpcontent/uploads/2014/06/aod2805.pdf.

Charlton RA, Neville AJ, Jordan S, Pierini A, Damase-Michel C, Klungsoyr K, Nybo Andersen AM, Vinkel Habsen A, Gini R, Bos JHJ, Puccini A, Hurault-Delarue C, Brooks CJ, de Jong-Van Den Berg LTW, de Vries CS. Healthcare databases in Europe for study medicine use and safety during pregnancy. Pharmacoepidemiol and Drug Saf. 2014 ;23:586-94.

Damase-Michel C, Lacroix I, Hurault-Delarue C, Beau AB, Montastruc JL. Evaluation des médicaments chez la femme enceinte : à propos de la base de données française EFEMERIS. Thérapie. 2014 ;69:91-100.

Damase-Michel C. Médicaments et consultation préconceptionnelle. In CD du 26e Forum de la Faculté de Médecine Toulouse Rangueil et Purpan le 26 octobre 2014.

Damase-Michel C, Hurault-Delarue C. Ibuprofen does not seem to increase global malformation risk but NSAID use in late pregnancy remains a concern. Evid Based Med. 2014 ;19:74.

Dehours E, Bounes V, Bagheri H, Valle B, Ducassé JL, Montastruc JL. Adverse drug reactions in an emergency medical dispatching centre. Eur J Clin Pharmacol. 2014 ;70:881-7.

Durrieu G, Batz A, Rousseau V, Bondon-Guitton E, Petiot D, Montastruc JL. Use of administrative database to identify adverse drug reactions in a pediatric university hospital. Eur J Clin Pharmacol. 2014 ;70:1519-26.

Elghozi JL, Senard JM. Prise en charge de l’hypotension orthostatique. AMC pratique. 2014 ;232:14-16.

Faillie JL, Azoulay L, Patenaude V, Hillaire-Buys D, Suissa S. Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes : cohort study. Br Med J. 2014 ;348:g2780

Faillie JL, Babai S, Crépin S, Bres V, Laroche ML, Le Louet H, Petit P, Montastruc JL, Hillaire-Buys D. French Pharmacovigilance Centers Network. Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors : a case/non-case study from the French Pharmacovigilance Database. Acta Diabetol. 2014 ;51:491-7.

Fournier JP, Sommet A, Durrieu G, Poutrain JC, Lapeyre-Mestre M, Montastruc JL. More on the « triple whammy » : antihypertensive drugs, non-steroidal anti-inflammatory agents and acute kidney injury – a case/non-case study in the french pharmacovigilance database. Ren Fail. 2014 ;36:1166-8.

Fournier JP, Sommet A, Durrieu G, Poutrain JC, Lapeyre-Mestre M, Montastruc JL. Drug interactions between antihypertensive drugs and non-steroidal anti-inflammatory agents : a descriptive study using the French pharmacovigilance database. Fundam Clin Pharmacol. 2014 ;28:230-5.

Fuzier R, Serres I, Bourrel R, Palmaro A, Montastruc JL, Lapeyre-Mestre M.  Analgesic drug consumption increases after knee arthroplasty : a pharmacoepidemiological study investigating postoperative pain. Pain. 2014 ;155:1339-45.

Gardette V, Lapeyre-Mestre M, Piau A, Gallini A, Cantet C, Montastruc JL, Vellas B, Andrieu S. A 2-year prospective cohort studuy of antidementia drug non-persistency in mild-to-moderate Alzheimer’s disease in Europe : predictors of discontinuation and switch in the ICTUS study. CNS Drugs. 2014 ;28:157-70.

Honton B, Despas F, Dumonteil N, Rouvellat C,Roussel M, Carrie D, Galinier M, Montastruc JL. Bortezomib and heart failure : case-report and review of the French Pharmacovigilance database. Fundam Clin Pharmacol. 2014 ;28:349-52.

Hurault Delarue C, Montastruc JL, Beau AB, Lacroix I, Damase-Michel C. Pregnancy outcome in women exposed to, dopamine agonists during pregnancy : a pharmacoepidemiology study in EFEMERIS database. Arch Gynecol Obstet. 2014 ;290:263-70

Jacquot J, Bagheri H, Montastruc JL. La notification d’effet indésirable au secours de l’ordonnance « non substituable » ! Thérapie. 2014 ;69:259-61.

Lapeyre-Mestre M. Médicament sans ordonnance : du mésusage à la dépendance. Paul Sabatier. 2014:25.

Le Moigne M, Sommet A, Lapeyre-Mestre M, Bourrel R, Molinier L, Paul C, Montastruc JL. Healthcare cost impact of biological drugs compared with traditional systemic treatments in psoriasis : a cohort analysis in the French insurance database. J Eur Acad Dermatol Venereol. 2014 ;28 :1235-44.

Loulergue P, Tubach F, Salmon D, Della monica P, Taillan B, Thorel JB, Marteau P, Bressot C, Ravaud P, Mariette X, Lortholary O, for the RATIO Group. Bacteremia in patients receiving TNF-alpha antagonists - a prospective multicenter study. Journal of Infection. 2013 ;67:524-8 (publié en 2014).

Molinier A, Acket B, Bourrel R, Lavezzi O, Montastruc JL, Bagheri H. Extrapolation des données physiopathologiques à la pratique clinique : à propos du dabigatran utilisé hors AMM. Press Med. 2014 ;43:468-9.

Montastruc F, Montastruc G, Taudou MJ, Olivier-Abbal P, Montastruc JL, Bondon-Guitton E. Acute coronary syndrome after nasal spray of oxymetazoline. Chest. 2014 ;146:e214-5.

Montastruc F, Retailleau, Rousseau V, Bagheri H, Montastruc JL. Atropinic burden of prescription forms in France : a study in community pharmacies in 2013. Eur J Clin Pharmacol. 2014 ;70:1147-48.

Montastruc F, Duguet C, Rousseau V, Bagheri H, Montastruc JL. Potentially inappropriate medications and adverse drug reactions in the elderly : a study in a pharmacovigilance database. Eur J Clin Pharmacol. 2014 ;70:1123-27.

Montastruc F, Scotto S, Vaz IR, Guerra LN, Escudero A, Sáinz M, Falomir T, Bagheri H, Herdeiro MT, Venegoni M, Montastruc JL, Carvajal A. Hepatotoxicity related to agomelatine and other new antidepressants : a case/noncase approach with information from the portuguese, French, spanish, and italian pharmacovigilance systems. J Clin Psychopharmacol. 2014 ;34:327-30.

Montastruc F, Moulis G, Palmaro A, Gardette V, Durrieu G, Montastruc JL. Interactions between Medical Residents and Drug Companies : A National Survey after the Mediator® Affair. PLoS One. 2014 Oct 3 ;9(10):e104828.

Montastruc JL. Statines : précisions. Rev Med Suisse. 2014 ;10:1089.

Montastruc JL, Laffon de Mazieres C, Montastruc F, Moulis G. Réflexions éthiques après l’affaire du Médiator®. Bulletin de liaison de l’association Mieux Prescrire. 2014 ;3:12.

Montastruc JL. Prescrire les statines à tout-va ?. Bioethique.com au service des soignants. 2014.

Montastruc P. Histoire de la pharmacologie clinique en France : dans une scintillante introspective, l’adaptation, l’évolution, la défense et l’illustration du médicament en France 1978-1981. Thérapie. 2014 ;69:481-482.

Moulis G, Palmaro A, Montastruc JL, Godeau B, Lapeyre-Mestre M, Sailer L. Epidemiology of incident immune thrombocytopenia : a nationwide population-based study in France. Blood 2014 ;124:3308-15.

Moulis G, Sommet A, Lapeyre-Mestre M, Montastruc JL ; on behalf of the Association Française des Centres Régionaux de PharmacoVigilance. Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor ? A case/non-case study in a nationwide pharmacovigilance database. Rheumatology. 2014 ;53:1864-71.

Moulis G, Bagheri H, Sailler L, Jonville-Bera AP, Weber E, Guy C, Petitpain N, Laroche ML, Favrelière S, Béné J, Baldin B, Villeval-Federici L, Tebacher-Alt M, Bres V, Veyrac G, Grandvuillemin A, The French Association of PharmacoVigilance Centers. Are adverse drug reaction patterns different between romiplostim and eltrombopag ? 2009-2013 French Pharmacovigilance assessment. Eur J Int Med. 2014 ;25:777-80.

Pages A, Bondon-Guitton E, Montastruc JL, Bagheri H. Undesirable effects related to oral antineoplastic drugs : comparison between patients’ internet narratives and a national pharmacovigilance database. Drug Saf. 2014 ;37:629-37.

Palosse-Cantaloube L, Lacroix I, Rousseau V, Bagheri H, Montastruc JL, Damase-Michel C. Analysis of chats on French internet forums about drugs ad pregnancy. Pharmacoepidemiol and Drug Saf. 2014 ;23:1330-3.

Perez-Lloret S, Rey MV, Crispo J, Krewski D, Lapeyre-Mestre M, Montastruc JL, Rascol O. Risk of heart failure following treatment with dopamine agonists in Parkinson’s disease patients. Expert Opin Drug Saf. 2014 ;13:351-60.

Pochard L, Hauviller L, Cuzin L, Eyvrard F, Sommet A, Montastruc JL, Bagherie H. Apport du logiciel Nadis® dans la collecte des effets indésirables des antirétroviraux : expérience en Midi-Pyrénées. Thérapie. 2014 ;69:149-55.

Reitter M, Petitpain N, Latarche C, Cottin J, Massy N, Demoly P, Gillet P, Mertes PM ; French Network of Regional Pharmacovigilance Centres. Fatal anaphylaxis with neuromuscular blocking agents : a risk factor and management analysis. Allergy. 2014 ;69:954-9.

Romio S, Weibel D, Dieleman JP, Olberg HK, de Vries CS, Sammon C, Andrews N, Svanström H, Mølgaard-Nielsen D, Hviid A, Lapeyre-Mestre M, Sommet A, Saussier C, Castot A, Heijbel H, Arnheim-Dahlström L, Sparen P, Mosseveld M, Schuemie M, van der Maas N, Jacobs BC, Leino T, Kilpi T, Storsaeter J, Johansen K, Kramarz P, Bonhoeffer J, Sturkenboom MC. Guillain-Barré syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccines : a multinational self-controlled case series in Europe. PLoS One. 2014 ;9:e82222.

Senard JM. L’hypotension orthostatique neurogène et ses traitements. Neurone. 2014 ;19:45-48.

Soussan C, Gouraud A, Portoloan G, Jean-Pastor MJ, Pecriaux C, Montastruc JL, Damase-Michel C. Drug-induced adverse reactions via breastfeeding : a descriptive study in the French pharmacovigilance database. Eur J Clin Pharmacol. 2014 ;70:1361-66.

Soussan-Dahan M, Lapeyre-Mestre M, Bondon-Guitton E, Delord JP, Despas F. Cetuximab cutaneous adverse drug reactions : a marker of efficacy for metastatic colorectal cancer and head-neck cancer ?. Thérapie. 2014 ;69:499-507.

Vrignaud L, Aouille J, Mallaret M, Durrieu G, Jonville-Béra AP. Hypersexualité induite par l’aripiprazole : à propos d’un cas et revue de la littérature. Thérapie. 2014 ;69:525-27.

Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F. Serotonin Syndrome : Analysis of Cases Registered in the French Pharmacovigilance Database. J Clin Psychophar. 2015 ;35:382-8.

Abadie D, Hurault-Delarue C, Damase-Michel C, Montastruc JL, Lacroix I. Medication exposure and spontaneous abortion : a case-control study using a French medical database. Clin Exp Obstet Gynecol. 2015 ;42:431-6.

Bénard-Laribière A, Miremont-Salamé G, Pérault-Pochat MC, Noize P, Haramburu F ; EMIR Study Group on behalf of the French network of pharmacovigilance centres. Incidence of hospital admissions due to adverse drug reactions in France : the EMIR study. Fundam Clin Pharmacol. 2015 ;29:106-11.

Bernard N, Jantzem H, Becker M, Pecriaux C, Bénard-Laribière A, Montastruc JL, Descotes J, Vial T ; French Network of Regional Pharmacovigilance Centres. Severe adverse effects of bromocriptine in lactation inhibition : a pharmacovigilance survey. BJOG. 2015 ;122:1244-51.

Berreni A, Montastruc F, Bondon-Guitton E, Rousseau V, Abadie D, Durrieu G, Chebane L, Giroud JP, Bagheri H, Montastruc JL. Adverse drug reactions to self-medication : a study in a pharmacovigilance database. Fundam Clin Pharmacol. 2015 Oct ;29(5):517-20.

Chayé H, Bernard M, Tubéry M, Rousseau V, Ecoiffier M, Montastruc JL, Bagheri H. Hospital readmission induced by adverse drug reaction : A pilot study in a post-emergency unit of a French university hospital. Rev Med Interne. 2015 ;36:450-6.

Chebane L, Bagheri H, Hillaire-Buys D, Géniaux H, Yahioui N, Laroche ML, Cottin J, Spreux A, Mosquet B, Pecriaux C, Bellet F, Lambert A, Montastruc JL. Pancréatites d’origine médicamenteuse. Revue des notifications spontanées en France. Drug-induced pancreatitis. A review of French spontaneous reports. Rev Med Int. 2015 ;36:573-78.

Courrier V, Fournier JP, Sommet A, Montastruc JL, Poutrain JC. Parenteral anticoagulants use in general practice : a cross-sectional study in south western France. Clin Appl Thromb Hemost. 2015 ;21:319-24.

Egron A, Olivier-Abbal P, Gouraud A, Babai S, Combret S, Montastruc JL, Bondon-Guitton E. Preventable and potentially preventable serious adverse reactions induced by oral protein kinase inhibitors through a database of adverse drug reaction reports. Targ Oncol. 2015 ;10:229-34.

Fournier JP, Yin H, Nessim SJ, Montastruc JL, Azoulay. Tramadol for non-cancer pain and the risk of hyponatremia. Am J Med. 2015 ;128:418-425.

Fournier JP, Azoulay L, Yin H, Montastruc JL, Suissa S. Tramadol Use and the Risk of Hospitalization for Hypoglycemia in Patients With Noncancer Pain. JAMA Intern Med. 2015 ;175:186-93.

Laccourreye O, Werner A, Giroud JP, Couloigner V, Bonfils P, Bondon-Guitton E. Benefits, limits and danger of ephedrine and pseudoephedrine as nasal decongestants. Eur Ann Otorhinolaryngol Head Neck Dis. 2015 ;132:31-4.

Lacroix I. Médicaments et allaitement. Duel effets pour bébé ? Science et santé. 2015 ;23:36.

Linselle M, Montastruc F, Jantzen H, Valnet-Rabier MB, Haramburu F, Coquerel A, Gouraud A, Perault-Pochat MC, Bagheri H, Montastruc JL. Drugs and Sleep Apneas ? A review of the French Pharmacovigilance database.Therapie. 2015 ;70:347-50.

Montastruc F, Rieu J, Letamendia C, Montastruc JL, Pathak A, Schmitt L. Measurement of QT interval and serotoninergic reuptake inhibitor antidepressants : a study in a university psychiatric hospital. L’Encéphale. 2015 ;41:282-283.

Montastruc F, Rouanet S, Gardette V, Rousseau V, Bagheri H, Montastruc JL. Atropinic burden of prescriptions forms in patients with Alzheimer disease : a cross-sectional study in a French PharmacoVigilance Database. Eur J Clin Pharmacol. 2015 ;71:891-5.

Montastruc F, Palmaro A, Bagheri H, Schmitt L, Montastruc JL, Lapeyre-Mestre M. Role of serotonin 5-HT2C and histamine H1 receptors in antipsychotic-induced diabetes : A pharmacoepidemiological-pharmacodynamic study in VigiBase. Eur Neuropsychopharmacol. 2015 ;25:1556-65.

Montastruc JL, Rousseau V, Chebane L, Abadie D, Bondon-Guitton E, Durrieu G, Montastruc F, Bagheri H. Hemorrhagic effects of oral anticoagulants : a comparative study between vitamin K antagonists (VKA) and direct oral anticoagulants (DOA). Eur J Clin Pharmacol. 2015 ;71:1283-84.

Moulis F, Moulis G, Balardy L, Gérard S, Sourdet S, Rougé-Bugat M, Lapeyre-Mestre M, Montastruc JL, Rolland Y, Vellas B. Searching for a Polypharmacy Threshold Associated With Frailty. J Am Med Dir Assoc. 2015 ;16:259-61.

Moulis F, Moulis G, Balardy L, Gérard S, Montastruc F, Sourdet S, Rougé-Bugat M, Lapeyre-Mestre M, Montastruc J, Rolland Y, Vellas B. Exposure to Atropinic Drugs and Frailty Status. J Am Med Dir Assoc. 2015 ;16:253-7.

Moulis G, Lapeyre-Mestre M, Mahévas M, Montastruc JL, Sailler L. Need for an improved vaccination rate in primary immune thrombocytopenia patients exposed to rituximab or splenectomy. A nationwide population-based study in France. Am J Hematol. 2015 ;90:301-5.

Moulis G, Lapeyre-Mestre M, Palmaro A, Pugnet G, Montastruc JL, Sailler L. French health insurance databases : What interest for medical research ? Rev Med Interne. 2015 ;36:411-17.

Moulis G, Lapeyre-Mestre M, Montastruc JL, Sailler L. Exposure to non-corticosteroid treatments in adult primary immune thrombocytopenia before the chronic phase in the era of thrombopoietin receptor agonists in France. A nationwide population-based study. Autoimmunity Reviews. 2015 ;14:168-73.

Moulis G, Audemard-Verger A, Arnaud L, Luxembourger C, Montastruc F, Gaman AM, Svenungsson E, Ruggeri M, Mahevas M, Gerfaud-Valentin M, Brainsky A, Michel M, Godeau B, Laurent G, Lapeyre-Mestre M, Sailler L. Thrombosis in Immune Thrombocytopenia Patients with Antiphospholipid Antibodies : A Meta-Analysis. Blood. 2015 ;126:1051.

Nguyen TTL, Palmaro A, Montastruc F, Lapeyre-Mestre M, Moulis G. Signal for Thrombosis with Eltrombopag and Romiplostim : A Disproportionality Analysis of Spontaneous Reports Within VigiBase®. Drug Saf. 2015 ;38:1179-86.

Palmaro A, Bissuel R, Renaud N, Durrieu G, Escourrou B, Oustric S, Montastruc JL, Lapeyre-Mestre M. Off-label prescribing in pediatric outpatients. Pediatrics. 2015 ;135:49-58.

Parant O, Deudon R, Benevent J, Viard C, Damase-Michel C, Guyard-Boileau B. Use of calcium channel blockers (CCB) for tocolysis in France and abroad. J Gynecol Obstet Biol Reprod (Paris). 2015 Apr ;44(4):312-23.

Pugnet G, Sailler L, Bourrel R, Montastruc JL, Lapeyre-Mestre M. Is Statin Exposure Associated with Occurrence or Better Outcome in Giant Cell Arteritis ? Results from a French Population-based Study. J Rheumatol. 2015 ;42:316-22.

Saliba L, Mondoly P, Duparc A, Bura-Rivière A, Maury P, Calmels V, Sallerin B, Pathak A, Montastruc JL, Bagheri H. Factors Associated with Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients with Non-valvular Atrial Fibrillation. Thérapie. 2015 ;70:485-92.

Thorel J, Civade E, Quintyn JC, Cestac P, Montastruc JL, Bagheri H. Ischaemic stroke after exposure to aflibercept : interaction with vitamin K antagonist and/or direct pharmacodynamic effect ? J Clin Pharm Ther. 2015 ;40:477-79.

Alberto C, Konstantinou MP, Martinage C, Casassa E, Tournier E, Bagheri H, Sibaud V, Mourey L, Mazereeuw-Hautier J, Meyer N, Paul C, Bulai Livideanu C. Enzalutamide induced acute generalized exanthematous pustulosis. J Dermatol Case Rep. 2016 ;10 : 35-38.

Bagheri H, Laroche ML, Montastruc JL. Les nouveaux défis de la pharmacovigilance. Therapie. 2 016 ;71:119-20.

Bagheri H, Laroche ML, Montastruc JL. Pharmacovigilance : The new challenges. Therapie. 2016 ;71:121-22.

Bagheri H, Lacroix I, Guitton-Bondon E, Damase-Michel C, Montastruc JL. Cyberpharmacovigilance : What is the usefulness of the social networks in pharmacovigilance ?. Therapie. 2016 ;71:235-39.

Bagheri H, Lacroix I, Guitton-Bondon E, Damase-Michel C, Montastruc JL. Cyberpharmacovigilance : les réseaux sociaux sont-ils utiles en pharmacovigilance ?. Therapie. 2016 ;71:229-33.

Beau AB, Montastruc JL, Lacroix I, Montastruc F, Hurault-Delarue C, Damase-Michel C. Atropinic burden of drugs during pregnancy and psychological development of children : a cohort study in the EFEMERIS database. Br J Clin Pharmacol. 2016 ;82:478-486.

Béné J, Moulis G, Bennani I, Auffret M, Coupe P, Babai S, Hillaire-Buys D, Micallef J, Gautier S ; French Association of Regional PharmacoVigilance Centres. Bullous pemphigoid and dipeptidyl peptidase IV-inhibitors : A Case/Non-Case study in the French Pharmacovigilance Database. Br J Dermatol. 2016 ;175:296-301.

Bondon-Guitton E, Combret S, Pérault-Pochat MC, Stève-Dumont M, Bagheri H, Huguet F, Despas F, Pathak A, Montastruc JL. Cardiovascular risk profile of patients with peripheral arterial occlusive disease during nilotinib therapy. Target Oncol. 2016 ;11:549-552.

Bondon-Guitton E, Despas F, Becquemont L. The contribution of pharmacogenetics to pharmacovigilance. Therapie. 2016 ;71:223-28.

Bondon-Guitton E, Despas F, Becquemont L. Apport de la Pharmacogénétique à la pharmacovigilance. Therapie. 2016 ;71:217-22.

Bounhoure JP, Bouvenot G, Montastruc JL. Cardiovascular risks and nonsteroidal anti-inflammatory drugs in the elderly recommendations for prescription. Bull. Acad. Natle Méd., 2015 ;199:949-957.

Bourgeois AL, Auriche P, Palmaro A, Montastruc JL, Bagheri H. Risk of hormonotherapy in transgender people : Literature review and data from the French Database of Pharmacovigilance. Ann Endocrinol (Paris). 2016 ;77:14-21.

Bouvenot G, Bounhoure JP, Montastruc JL, Vacheron A. Rapport sur les anticoagulants oraux directs (AOD), (antérieurement appelés « nouveaux anticoagulants oraux » ou NACO). Bull. Acad. Natle Méd..2014 ;198:1157-1195.

De Germay S, Montastruc JL, Rousseau V, Chebane L, Bondon-Guitton E, Moulis F, Durrieu G, Bagheri H, Rascol O, Pariente A, Bégaud B, Montastruc F. Atropinic (Anticholinergic) Burden in Parkinson’s Disease. Mov Disord. 2016 ;31:632-6.

Durrieu G, Jacquot J, Mège M, Bondon-Guitton E, Rousseau V, Montastruc F, Montastruc JL. Completeness of Spontaneous Adverse Drug Reaction Reports Sent by General Practitioners to a Regional Pharmacovigilance Centre : A Descriptive Study. Drug Saf. 2016 ;39:1189-1195.

Faillie JL, Montastruc F, Montastruc JL, Pariente A. L’apport de la pharmaco-épidémiologie à la pharmacovigilance. Therapie. 2016 ;71:203-09.

Faillie JL, Montastruc F, Montastruc JL, Pariente A. Pharmacoepidemiology and its input to pharmacovigilance. Therapie. 2016 ;71:211-16.

Giroud JP, Montastruc JL. Séance thématique : La Pharmacoépidémiologie. Bull Acad Natle Med. 2015 ;199:261-62.

Giroud JP, Montastruc JL. Les médicaments du rhume à base de vasoconstricteurs doivent être prescrits sur ordonnance. Bull. Acad. Natle Méd..2015 ;199:947-48.

Guinard E, Bulai Livideanu C, Barthelemy H, Viguier M, Reguiai Z, Richard MA, Jullien D, Beneton N, Bara C, Vabres P, Grandvuillemin A, Marguery MC, Amelot F, Konstantinou MP, Bagheri H, Paul C ; for the French Psoriasis Research Group. Active tuberculosis in psoriasis patients treated with TNF antagonists : a French nationwide retrospective study. JEADV. 2016 ;30:1336-41.

Hallberg P, Eriksson N, Ibañez L, Bondon-Guitton E, Kreutz R, Carvajal A, M Isabel Lucena M, Sancho Ponce E, Molokhia M, Martin J, Axelsson T, Yue QY, K E Magnusson P, Wadelius M, for the EuDAC collaborators*. Genetic variants associated with antithyroid drug-induced agranulocytosis : a genome-wide association study in a European population. Lancet Diabetes Endocrinol. 2016 ;4:507-16.

Hauviller L, Eyvrard F, Garnault V, Rousseau V, Molinier L, Montastruc JL, Bagheri H. Hospital re-admission associated with adverse drug reactions in patients over the age of 65 years. Eur J Clin Pharmacol. 2016 ;72:631-9.

Hurault-Delarue C, Chouquet C, Savy N, Lacroix I, Beau AB, Montastruc JL, Damase-Michel C. How to take into account exposure to drugs over time in pharmacoepidemiology studies of pregnant women ? Pharmacoepidemiol Drug Saf. 2016 ;25:770-77.

Hurault-Delarue C, Damase-Michel C, Finotto L, Guitard C, Vayssière C, Montastruc JL, Montastruc F, Lacroix I. Psychomotor developmental effects of prenatal exposure to psychotropic drugs : a study in EFEMERIS database. Fund Clin Pharmacol. 2016 ;30:476-482.

Lacroix I, Beau AB, Hurault-Delarue C, Bouilhac C, Petiot D, Vayssière C, Vidal S, Montastruc JL, Damase-Michel C. First epidemiological data for venotonics in pregnancy from the EFEMERIS database. Phlebology. 2016 ;31:344-8.

Mauran A, Goze T, Abadie D, Bondon-Guitton E, Chevrel P, Schmitt L, Montastruc JL, Montastruc F. Mania associated to Ranitidine : a case report and review of literature. Fundam Clin Pharmacol. 2016 ;30:294-6.

Montastruc F, Salvo F, Arnaud M, Bégaud B, Pariente A. Signal of Gastrointestinal Congenital Malformations with Antipsychotics After Minimising Competition Bias : A Disproportionality Analysis Using Data from Vigibase®. Drug Saf. 2016 ;39:689-96.

Montastruc F, Montastruc G, Montastruc JL, Revet A. Cardiovascular safety of methylphenidate should also be considered in adults !. Bmj. 2016 ;353:i3418.

Montastruc JL, Chebane L, Bagheri H. Drug-Induced Hyperglycaemia and Diabetes. Drug Saf. 2016 ;39:465-66.

Montastruc JL, Emmanuelle Bondon-Guitton E, Abadie D, Lacroix I, Berrenia A, Pugnet G, Durrieu G, Sailler L, Giroudb JP, Damase-Michel M, Montastruc F. Pharmacovigilance : Risques et effets indésirables de l’automédication. Therapie. 2016 ;71:249-255.

Montastruc JL, Emmanuelle Bondon-Guitton E, Abadie D, Lacroix I, Berrenia A, Pugnet G, Durrieu G, Sailler L, Giroudb JP, Damase-Michel M, Montastruc F. Pharmacovigilance, risks and adverse effects of self-medication. Therapie. 2016 ;71:257-262.

Montastruc JL, Sommet A, Montastruc F, Moulis G, Bagheri H, Damase-Michel M, Lapeyre-Mestre M.  Qu’est-ce que la pharmacoépidémiologie. Pharmacoepidemiology : definition, methods and applications. Bull Acad Natle Med. 2015 ;199:263-73.

Olivier-Abbal P. Mesure de l’évitabilité des effets indésirables médicamenteux en France : état des lieux en 2015. Therapie. 2016 ;71:187-194.

Olivier-Abbal P. Measuring the preventability of adverse drug reactions in France : A 2015 overview. Therapie. 2016 ;71:195-202.

Olivier-Abbal P, Gimbert A, Colin AL, Salvo F, Becker M, Marty V, Montastruc JL, Petitpain N. Serious adverse drug events related to non-investigational drugs in academic clinical trials : another source of safety data for risk assessment ? Br J Clin Pharmacol. 2016 ;82:1069-75.

Palosse-Cantaloube L, Hurault-Delarue C, Beau AB, Montastruc JL, Lacroix I, Damase-Michel C. Risk of infections during the first year of life after in utero exposure to drugs acting on immunity : a population-based cohort study. Pharmacol Res. 2016 ;113:557-52.

Pugnet G, Sailler L, Fournier JP, Bourrel R, Montastruc JL, Lapeyre-Mestre M.  Predictors of Cardiovascular Hospitalization in Giant Cell Arteritis : Effect of Statin Exposure. A French Population-based Study. J Rheumatol. 2016 ;43:2162-2170.

Récoché I, Rousseau V, Bourrel R, Lapeyre-Mestre M, Chebane L, Despas F, Montastruc JL, Bondon-Guitton E. Drug-drug interactions with imatinib : An observational study. Medicine (Baltimore). 2016 ;95:e5076.

Saliba L, Moulis G, Abou Taam M, Rousseau V, Chebane L, Petitpain N, Baldin B, Pugnet G, Montastruc JL, Bagheri H. Tumor necrosis factor inhibitors added to nonbiological immunosuppressants vs. nonbiological immunosuppressants alone : a different signal of cancer risk according to the condition. A disproportionality analysis in a nationwide pharmacovigilance database. Fundam Clin Pharmacol. 2016 ;30:162-71.

Thorel J, McCambridge C, Piau A, Secher M, Magre É, Montastruc JL, Bagheri H. Proton pump inhibitors : Real indication or trivialized prescription ?. Therapie. 2016 ;71:589-93.

Tournaire G, Despas F, Huguet F, Montastruc JL, Bondon-Guitton E. Peripheral arterial occlusive disease during ponatinib therapy after failure of imatinib : a case report. J Clin Pharm Ther. 2016 ;41:360-61.

Tranchard F, Hein C, Lacombe J, Villars H, Montastruc JL, Despas F. Medication errors and look-alike tablets : the splitting issue. Pharmacoepidemiol Drug Saf. 2016 ;25:1002-3.

Villeneuve C, Laroche ML, Essig M, Merville P, Kamar N, Coubret A, Lacroix I, Bouchet S, Fruit D, Marquet P, Rousseau A ; EPIGREN study group. Evolution and Determinants of Health-Related Quality-of-Life in Kidney Transplant Patients Over the First 3 Years After Transplantation. Transplantation. 2016 ;100:640-7.

Abadie D, Essilini A, Montastruc F, Fulda V, Gouraud A, Yéléhé-Okouma M, Jean-Pastor M, Montastruc JL. Drug-induced panic attacks : analysis of cases registered in the French pharmacovigilance database. J Psychiatr Res. 2017 ;90:60-66.

Allain N, Leven C, Falissard B, Allain JS, Batail JM, Polard E, Montastruc F, Drapier D, Naudet F. Manic switches induced by antidepressants : an umbrella review comparing randomized controlled trials and observational studies. Acta Psychiatr Scand. 2017 ;135:106-116.

Beau AB, Tauber M, Chollet C, Hurault-Delarue C, Bouilhac C, Montastruc JL, Lacroix I, Damase-Michel C. A contemporary description of French newborns’ growth using the Efemeris cohort. Arch Pediatr. 2017 ;24:424-431.

Beau AB, Didier A, Hurault-Delarue C, Montastruc JL, Lacroix I, Damase-Michel C. Prescription of asthma medications before and during pregnancy in France : An observational drug study using the EFEMERIS database. J Asthma. 2017 ;54:258-264.

Benevent J, Montastruc F, Damase-Michel C. The importance of pharmacoepidemiology in pregnancy-implications for safety. Expert Opin Drug Saf. 2017 ;16:1181-90.

Benevent J, Bouton J, Damase-Michel C. Effets indésirables gynécologiques des anti-facteur de nécrose tumorale ; Gynaecological side effects of TNF-inhibitors. Rep Gyn End. 2017 ;19:146-52.

Bondon-Guitton E, Mourgues T, Rousseau V, Cousty S, Cottin J, Drablier G, Micallef J, Montastruc JL. Gingival bleeding, a possible "serious" adverse drug reaction : An observational study in the French PharmacoVigilance Database. J Clin Periodontol. 2017 ;44:898-904.

Bouvenot G, Sassard J, Montastruc JL. For an optimal use of fixed drug combinations. Therapie. 2017 ;72:665-668.

Cabarrot A, Montastruc JL, Chebane L, Rousseau V, Bondon-Guitton E, Moulis F, Durrieu G, Bagheri H, Montastruc F. Neurological and Digestive Bleeding with Direct Oral Anticoagulants versus Vitamin K Antagonists : the differences do not stop there ! A pharmacovigilance study. Pharmacol Res. 2017 ;118:119-120.

Caillet C, Sichanh C, Assemat G, Malet-Martino M, Sommet A, Bagheri H, Sengxeu N, Mongkhonmath N, Mayxay M, Syhakhang L, Lapeyre-Mestre M, Newton PN, Roussin A. Role of Medicines of Unknown Identity in Adverse Drug Reaction-Related Hospitalizations in Developing Countries : Evidence from a Cross-Sectional Study in a Teaching Hospital in the Lao People’s Democratic Republic. Drug Saf. 2017 ;40:809-821.

Chatelet JN, Auffret M, Combret S, Bondon-Guitton E, Lambert M, Gautier S. Hydroxychloroquine-induced hearing loss : First case of positive rechallenge and analysis of the French pharmacovigilance database. Rev Med Interne. 2017 ;38:340-343.

Couture G, Delzor F, Bagheri H, Micallef J, Ruyssen-Witrand A, Laroche M. First cases of calcium pyrophosphate deposition disease after zoledronic acid therapy. Joint Bone Spine. 2017 ;84:213-215.

Durrieu G, Jacquot J, Baudrin D, Mège M, Rousseau V, Bagheri H, Bondon-Guitton E, Abadie D, Montastruc F, Bismuth M, Oustric S, Montastruc JL. Improving adverse drug reaction reporting by general practitioners through clinical research assistants visits. Therapie. 2016 ;72:351-355.

Faillie JL, Ferrer P, Gouverneur A, Driot D, Berkemeyer S, Vidal X, Martínez-Zapata MJ, Huerta C, Castells X, Rottenkolber M, Schmiedl S, Sabaté M, Ballarín E, Ibáñez L. A new risk of bias checklist applicable to randomized trials, observational studies, and systematic reviews was developed and validated to be used for systematic reviews focusing on drug adverse events. J Clin Epidemiol. 2017 ;86:168-175.

Formoso G, Font-Pous M, Ludwig WD, Phizackerley D, Bijl D, Erviti D, Pospisilova B, Montastruc JL. Drug information by public health and regulatory institutions : results of an 8-coutry survey in Europe. Health Policy. 2017:121 ;257-264.
16. Gautier Y, Montastruc F. Pharmacovigilance, une consultation pour les pathologies médicamenteuses. Le Moniteur des Pharm. 2017 ;3158:19.

Gicquel C, Moulis F, Chenaf C, Gouraud A, Drici M, Bondon-Guitton E, Montastruc F, Montastruc JL. Duloxetine and gingival bleeding : a case-report and reviews of the French and World PharmacoVigilance Databases and literature. Eur J Clin Pharmacol. 2017 ;73:1197-98.

Graner S, Svensson T, Beau AB, Damase-Michel C, Engeland A, Furu K, Hviid A, Haberg SE, Molgaard-Nielsen D, Pasternak B, Kieler H. Neuraminidase inhibitors during pregnancy and risk of adverse neonatal outcomes and congenital malformations : population based European register study. BMJ. 2017 ;356:j629.

Humbert X, Dolladille C, Sassier M, Valnet-Rabier MB, Vial T, Guitton E, Page A, Sole E, Auriche P, Coquerel A, Alexandre J, Fedrizzi S. Fibrates and risk of venous thromboembolism : Case/no-case study in French pharmacovigilance database. Therapie. 2017 ;72:677-682.

Hurault-Delarue C, Chouquet C, Savy N, Lacroix I, Beau AB, Montastruc JL, Damase-Michel C. Interest of the trajectory method for the evaluation of outcomes after in utero drug exposure : example of anxiolytics and hypnotics. Pharmacoepidemiol Drug Saf. 2017 ;26:561-569.

Linselle M, Sommet A, Bondon-Guitton E, Moulis F, Durrieu G, Benevent J, Rousseau V, Chebane L, Bagheri H, Montastruc F, Montastruc JL. Can drugs induce or aggravate Sleep Apneas ? A case non case Study in Vigibase®, the WHO Pharmacovigilance Database. Fundam Clin Pharmacol. 2017 ;31:359-366.

Molinier A, Palmaro A, Rousseau V, Sommet A, Bourrel R, Montastruc JL, Bagheri H. Does substitution of brand name medications by generics differ between pharmacotherapeutic classes ? A population-based cohort study in France. Eur J Clin Pharmacol. 2017.73 ;471-77.

Montastruc F, Benevent J, Rousseau V, Chebane L, Bondon‐Guitton E, Durrieu D, Montastruc JL, Sommet A. Statins and diabetes : Is there any difference between the different statins ?. Pharmacoepidemiol Drug Saf. 2017 ;26:1296-1297.

Montastruc F, Moulis F, Araujo M, Chebanne L, Rascol O, Montastruc JL. Ergot and non-ergot dopamine agonists and heart failure in patients with parkinson’s disease. Eur Jour Clin Phar. 2017 ;73:99-103.

Montastruc F, Sommet A, Montastruc JL. Concomitant medications and obstructive sleep apnoea. Br J Clin Pharmacol. 2017 ;83:2315-2316.

Montastruc J, Marque P, Moulis F, Bourg V, Lambert V, Durrieu G, Montastruc JL, Montastruc F. Adverse drug reactions of botulinum neurotoxin type A in children with cerebral palsy : a pharmaco-epidemiological study in VigiBase. Dev Med Child Neurol. 2017 ;59:329-334.

Montastruc JL, Durrieu G, Lacroix I, Lapeyre-Mestre M, Damase-Michel C, Bagheri H, Sommet A. Quelle Pharmacovigilance pour les vaccins ?. Bull. Acad. Natle. Mèd. Publi 2016. 2017 ;200:35.

Moulis F, Rousseau V, Abadie D, Masmoudi K, Micallef J, Vigier C, Pierre S, Dautriche A, Montastruc F, Montastruc JL. Serious adverse drug reactions with tramadol reported to the French pharmacovigilance database between 2011 and 2015.Therapie. 2017 ;72:615-624.

Nicoletti P, Aithal GP, Bjornsson ES, Andrade RJ, Sawle A, Arrese M, Barnhart HX, Bondon-Guitton E, Hayashi PH, Bessone F, Carvajal A, Cascorbi I, Cirulli ET, Chalasani N, Conforti A, Coulthard SA, Daly MJ, Day CP, Dillon JF, Fontana RJ, Grove JI, Hallberg P, Hernández N, Ibáñez L, Kullak-Ublick GA, Laitinen T, Larrey D, Lucena MI, Maitland-van der Zee AH, Martin JH, Molokhia M, Pirmohamed M, Powell EE, Qin S, Serrano J, Stephens C, Stolz A, Wadelius M, Watkins PB, Floratos A, Shen Y, Nelson MR, Urban TJ, Daly AK ; International DILI consortium (iDILIC), Drug-induced liver injury network (DILIN) investigators and International Serious Adverse Events Consortium (iSAEC). Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-wide Association Study. Gastroenterology. 2017 ;152:1078-1089.

Nguyen TTH, Pariente A, Montastruc JL, Lapeyre-Mestre M, Rousseau V, Rascol O, Bégaud B, Montastruc F. An original pharmacoepidemiologic - pharmacodynamic method : application to antipsychotic-induced movement disorders. Br J Clin Pharmacol. 2017 ;83:612-622.

Ojero-Senard A, Benevent J, Bondon-Guitton E, Durrieu G, Chebane L, Araujo M, Montastruc F, Montastruc JL. A comparative study of QT prolongation with serotonin reuptake inhibitors. Psychopharmacology. 2017 ;234:3075-81.

Patras de Campaigno E, Kebir I, Montastruc JL, Rueter M, Maret D, Lapeyre-Mestre M, Sallerin B, Despas F. Drug-Induced Dental Caries : A Disproportionality Analysis Using Data from VigiBase. Drug Saf. 2017 ;40:1249-1258.

Patras de Campaigno E, Bondon-Guitton E, Laurent G, Montastruc F, Montastruc JL, Lapeyre-Mestre M, Despas F. Identification of Cellular targets involved in cardiac failure caused by PKI in oncology : an approach combining Pharmacovigilance and Pharmacodynamics. Br J Clin Pharmacol. 2017 ;83:1544-1555.

Ravoire S, Lang M, Perrin E ; participants of Giens XXXII Round Table No. 6. Audry A, Bilbault P, Chekroun M, Demerville L, Escudier T, Guéroult-Accolas L, Guillot C, Malbezin M, Maugendre P, Micallef J, Molimard M, Montastruc F, Pierron E, Reichardt L, Thiessard F. Advantages and limitations of online communities of patients for research on health products. Therapie. 2017 ;72:135-143.

Ravoire S, Lang M, Perrin E ; les participants à la table ronde N° 6 de Giens XXXII. Audry A, Bilbault P, Chekroun M, Demerville L, Escudier T, Guéroult-Accolas L, Guillot C, Malbezin M, Maugendre P, Micallef J, Molimard M, Montastruc F, Pierron E, Reichardt L, Thiessard F. Intérêts et limites des communautés virtuelles de patients pour la recherche sur les produits de santé. Therapie. 2017 ;72:125-134.

Severino-Freire M, Lamant L, Bagheri H, Mazereeuw-Hautier J, Paul C. Drug eruption with clomifene citrate in a bodybuilder. Ann Dermatol Venereol. 2017 ;144:636-637.

Salgues M, Damase-Michel C, Montastruc JL, Lacroix I. Women’s knowledge of folic acid. Therapie. 2017 ;72:339-343.

Sommet A, Lapeyre-Mestre M. Drug Use and Mortality in Parkinson Disease. J Am Med Dir Assoc. 2017 ;18:989.

Thu Trang D, Cool C, Laffon de Mazieres C, Lapeyre-Mestre M, Montastruc JL, Rascol O, Rolland Y, Sommet A. Mortality and Antipsychotic Drug Use in Elderly Patients With Parkinson Disease in Nursing Homes. J Am Med Dir Assoc. 2017 ;18:791-796.

Bouquet É, Star K, Jonville-Béra AP, Durrieu G. Pharmacovigilance in pediatrics.Therapie. 2018 ;73:171-180.

Bouvenot G, Sassard J, Montastruc JL. Pour une utilisation optimale des associations fixes de médicaments. Recommandations de prescription. Bull. Acad. Natle Méd. 2017 ;201,41-44.

Couderc S, Lapeyre-Mestre M, Bourrel R, Carle P, Montastruc JL, Sommet A. Infectious risk of biological drugs versus traditional systemic treatments in moderate to severe psoriasis : a cohort analysis in the French insurance database. Fundam Clin Pharmacol. 2018 ;4:436-449.

Defer G, Le Caignec F, Fedrizzi S, Montastruc F, Chevanne D, Parienti JJ, Peyro-Saint-Paul L. Dedicated mobile application for drug adverse reaction reporting by patients with relapsing remitting multiple sclerosis (Vigip-SEP study) : study protocol for a randomized controlled trial.Trials. 2018 ;19:174.

Diaz H, Bagheri H, Palmaro A, Rousseau V, Bourrel R, Montastruc JL, Birebent J. Patterns of direct oral anticoagulant drug prescription in France in 2010-2013 : a study in the Midi-Pyrénées area. Eur J Clin Pharmacol. 2018 ;74:945-951.

Driot D, Figuet L, Birebent J, Coste S, Durrieu G, Jacquot J, Bismuth M. Satisfaction of a pharmacovigilance declaration support network in general practice. Therapie. 2018 ;73:483-493.

Durrieu G, Maupiler M, Rousseau V, Chebane L, Montastruc F, Bondon-Guitton E, Montastruc JL. Frequency and Nature of Adverse Drug Reactions Due to Non-Prescription Drugs in Children : A Retrospective Analysis from the French Pharmacovigilance Database. Paediatr Drugs. 2018 ;20:81-87.

El Chaer G, Lapeyre Mestre M. Tramadol : la crise des opioïdes de l’Afrique. Revue Prescrire. 2018 ;418:631.

Foch C, Araujo M, Weckel A, Damase-Michel C, Montastruc JL, Benevent J, Durrieu G, Lacroix I. In utero drug exposure and hearing impairment in 2-year-old children A case-control study using the EFEMERIS database. Int J Pediatr Otorhinolaryngol. 2018 ;113:192-197.

Kaguelidou F, Kassai Koupai B, Durrieu G. Pediatric pharmacology.Therapie. 2018 ;73:111-112.

Khouri C, Lepelley M, Roustit M, Montastruc F, Humbert M, Cracowski JL. Comparative safety of drugs targeting the nitric oxide pathway in pulmonary hypertension : a mixed approach combining a meta-analysis of clinical trials and a disproportionality analysis from the WHO pharmacovigilance database. Chest. 2018 ;154:136-147.

Mahé J, de Campaigno EP, Chené AL, Montastruc JL, Despas F, Jolliet P. Pleural adverse drugs reactions and protein kinase inhibitors : Identification of suspicious targets by disproportionality analysis from VigiBase. Br J Clin Pharmacol. 2018 ;84:2373-2383.

Montastruc F, Bénard-Laribière A, Noize P, Pambrun E, Diaz-Bazin F, Tournier M, Bégaud B, Pariente A. Antipsychotics use : 2006-2013 trends in prevalence and incidence and characterization of users. Eur J Clin Pharmacol. 2018 ;74:619-626.

Montastruc F, Benevent J, Touafchia A, Chebane L, Araujo M, Guitton-Bondon E, Durrieu G, Arbus C, Schmitt L, Begaud B, Montastruc JL. Atropinic (Anticholinergic) Burden in Antipsychotic-Treated Patients. Fundam Clin Pharmacol. 2018 ;32:114-119.

Montastruc F, Bagheri H, Lacroix I, Damase-Michel C, Chebane L, Rousseau V, Jouanjus E, Lapeyre-Mestre M, Durrieu G, Montastruc JL. Adverse Drug Reaction Reports Received Through the Mobile App, VigiBIP® : A Comparison with Classical Methods of Reporting. Drug Saf. 2018 ;41:511-514.

Montastruc F, Benevent J, Rousseau V, Durrieu G, Sommet A, Montastruc JL. Risk of Diabetes with Fibrates and Statins : a pharmacoepidemiological study in Vigibase®. Fundam Clin Pharmacol. 2018 Aug 11. doi : 10.1111/fcp.12406. [Epub ahead of print]

Montastruc F, Benevent J, Chebane L, Rousseau V, Durrieu G, Sommet A, Montastruc JL. Vomiting and constipation associated with tramadol and codeine : a comparative study in VigiBase®. Eur J Clin Pharmacol. 2018 Aug 10. doi : 10.1007/s00228-018-2536-z. [Epub ahead of print].

Montastruc F, Khosrow-Khavar F, de Germay S, Renoux C, Rousseau V, Durrieu G, Montastruc M, Rascol O, Sommet A, Lapeyre-Mestre M, Benevent J, Montastruc JL. Tamoxifen and the risk of Parkinsonism : a case/non-case study. Eur J Clin Pharmacol. 2018 ;74:1181-1184.

Moulis F, Rousseau V, Chebane L, Gouverneur A, Gaboriau L, Faillie JL, Durrieu G, Montastruc F, Montastruc JL. Serious adverse drug reactions with sacubitril/valsartan Entresto® : a French pharmacovigilance survey. Eur J Clin Pharmacol. 2018 ;74:983-84.

Moulis F, Durrieu G, Masmoudi K, Gervoise Boyer M, Rocher F, Montastruc F, Montastruc JL. Medication errors with tramadol drops in children. Eur J Clin Pharmacol. 2018 ;74:247-248.

Moulis F, Durrieu G, Lapeyre-Mestre M. Off-label and unlicensed drug use in children population. Therapie. 2018 ;73:135-149.

Nguyen TTH, Roussin A, Rousseau V, Montastruc JL, Montastruc F. Role of Serotonin Transporter in Antidepressant-Induced Diabetes Mellitus : A Pharmacoepidemiological–Pharmacodynamic Study in VigiBase. Drug Safety. 2018. https://doi.org/10.1007/s40264-018-0693-8

Nguyen KD, Nguyen PT, Nguyen HA, Roussin A, Montastruc JL, Bagheri H, Olsson S. Overview of Pharmacovigilance System in Vietnam : Lessons Learned in a Resource-Restricted Country. Drug Saf. 2018 ;41:151-159.

Perez C, Olivier P, Lortal B, Duranton S, Montastruc JL, Colin AL, Toulza E, Becker M, Hamy L, Crepin S, Roussillon C, Gimbert A, Petitpain N, Salvo F. Detection of drug safety signals from clinical trials data : Role of SUSARs. Pharmacol Res. 2018 ;131:218-223.

Revet A, Montastruc F, Raynaud JP, MD, Baricault B, Montastruc JL, Maryse Lapeyre-Mestre M. Trends and Patterns of Antidepressant Use in French Children and Adolescents From 2009 to 2016. A Population-Based Study in the French Health Insurance Database. Journal of Clinical Psychopharmacology. 2018 ;38:327-335.

Reynolds E, Guénette L, Lexchin J, Cassels A, Wilkes MS, Durrieu G, Beaulieu MD, Mintzes B. Reconciling a "pleasant exchange" with evidence of information bias : A three-country study on pharmaceutical sales visits in primary care. Health Policy. 2018 ;122:250-255.

Rwagitinywaa J, Sommet A, Palmaro A, Montastruc JL, Lapeyre-Mestre M. Utilization and costs of HIV antiretroviral drugs in Europe during thelast ten years : Impact of generic antiretroviral drugs on cost reduction. Health Policy. 2018 ;122:237-242.

Rwagitinywa J, Lapeyre-Mestre M, Bourrel R, Montastruc JL, Sommet A. Comparison of adherence to generic multi-tablet regimens versus brand multi-tablet and brand single-tablet regimens likely to incorporate generic antiretroviral drugs by breaking or not fixed-dose combinations in HIV-infected patients. Fundam Clin Pharmacol. 2018 Mar 5. doi : 10.1111/fcp.12363. [Epub ahead of print]

Wadelius M, Eriksson N, Kreutz R, Bondon-Guitton E, Ibañez L, Carvajal A, Lucena MI, Sancho Ponce E, Molokhia M, Martin J, Axelsson T, Kohnke H, Yue QY, Magnusson PKE, Bengtsson M, Hallberg P ; EuDAC. Sulfasalazine-induced agranulocytosis is associated with the human leukocyte antigen locus. Clin Pharmacol Ther. 2017 Aug 1. doi : 10.1002/cpt.805. [Epub ahead of print]

Andre L, Gallini A, Montastruc F, Coley N, Montastruc JL, Vellas B, Andrieu S, Gardette V ; MAPT/DSA study group. Anticholinergic exposure and cognitive decline in older adults : Effect of anticholinergic exposure definitions in a 3-year analysis of the Multidomain Alzheimer Preventive Trial (MAPT) study. Br J Clin Pharmacol. 2019 ;85:71-99.

Andre L, Gallini A, Montastruc F, Montastruc JL, Piau A, Lapeyre-Mestre M, Gardette V. Association between anticholinergic (atropinic) drug exposure and cognitive function in longitudinal studies among individuals over 50 years old : a systematic review. Eur J Clin Pharmacol. 2019 ;75:1631-1644.

Araujo M, Hurault-Delarue C, Bouilhac C, Petiot D, Benevent J, Vayssière C, Vidal S, Montastruc JL, Damase-Michel C, Lacroix I. Non-Steroidal Anti-Inflammatory Drug (NSAID) Prescriptions from the 6th Month of Pregnancy : Impact of Advice from Health Authorities. Fundam Clin Pharmacol. 2019 ;33:581-588.

Bagheri H. Interest of pharmacoepidemiology for the study of anticoagulants. Therapie. 2019 ;74:245-248.

Bataillard M, Beyens MN, Mounier G, Vergnon-Miszczycha D, Bagheri H, Cathebras P. Muscle Damage Due to Fusidic Acid-Statin Interaction : Review of 75 Cases From the French Pharmacovigilance Database and Literature Reports. Am J Ther. 2019 ;26:e375-e379.

Baudou E, Benevent J, Montastruc JL, Touati G, Hachon Le Camus C. Adverse Effects of Treatment with Valproic Acid during the Neonatal Period. Neuropediatrics. 2019 ;50:31-40.

Bégaud B, Montastruc JL. Pharmacoepidemiology, the new paradigm of drug evaluation. Therapie. 2019 ;74:167-168.

Benevent J, Lacroix I. Medication and pregnancy, asssessing the risk-benefit balance. Actualités pharmaceutiques. 2019 ;588:21-27.

Benevent J, Araujo M, Hurault-Delarue C, Montastruc JL, Sommet A, Lacroix I, Damase-Michel C. Pharmacoepidemiology in pregnancy. Therapie. 2019 ;74:289-300.

Benevent J, Hurault-Delarue C, Araujo M, Montastruc JL, Lacroix I, Damase-Michel C. POMME : The New Cohort to Evaluate Long-Term Effects After Prenatal Medicine Exposure. Drug Saf. 2019 ;42:45-54.

Benevent J, Hurault-Delarue C, Araujo M, Montastruc F, Montastruc JL, Lacroix I, Damase-Michel C. Higher intake of medications for digestive disorders in children prenatally exposed to drugs with atropinic properties. Fundam Clin Pharmacol. 2018 ;33:314-326.

Berger E, Delpierre C, Despas F, Bertoli S, Bérard E, Bombarde O, Bories P, Sarry A, Laurent G, Récher C, Lamy S. Are social inequalities in acute myeloid leukemia survival explained by differences in treatment utilization ? Results from a French longitudinal observational study among older patients. BMC Cancer. 2019 ;19:883.

Carr DF, Francis B, Jorgensen AL, Zhang E, Chinoy H, Heckbert SR, Bis JC, Brody JA, Floyd JS, Psaty BM, Molokhia M, Lapeyre-Mestre M, Conforti A, Alfirevic A, van Staa T, Pirmohamed M. Genomewide Association Study of Statin-Induced Myopathy in Patients Recruited Using the UK Clinical Practice Research Datalink. Clin Pharmacol Ther. 2019 ;106:1353-1361.

Charlton R, Damase-Michel C, Hurault-Delarue C, Gini R, Loane M, Pierini A, Puccini A, Neville A, Snowball J, Morris JK ; EUROmediSAFE consortium. Did advice on the prescription of sodium valproate reduce prescriptions to women ? An observational study in three European countries between 2007 and 2016. Pharmacoepidemiol. Drug Saf. 2019 ;28:1519-1528.

Clapes V, Rousseau R, Despas F, Montastruc JL, Olivier P. Adverse Drug Reactions Involving Protein Kinase Inhibitors : A French Pharmacovigilance Database Study Comparing Safety in Younger and Older Patients (≥ 75 years) with Cancer. Pharmaceutical Medicine. 2018 ;33:21-27.

Compaci G, Conte C, Oberic L, Ysebaert L, Laurent G, Despas F. Sustained degradation of quality of life in a subgroup of lymphoma survivors : a two-year prospective survey. BMC Cancer. 2019 ;19:1178.

Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran AA, Toutain PL. Levothyrox® New and Old Formulations : Are they Switchable for Millions of Patients ? Clinical Pharmacokinetics. 2019 ;58:827-833.

Concordet D, Gandia P, Montastruc JL, Bousquet‑Mélou A, Lees P, Ferran AA, Toutain PL. Authors’ Reply to Lechat et al. Levothyrox® New and Old Formulations : Are they Switchable for Millions of Patients ? Clinical Pharmacokinetics. 2019 ;58:13553-1354.

Concordet D, Gandia P, Montastruc JL, Bousquet‑Mélou A, Lees P, Ferran AA, Toutain PL. Authors’ Reply to Nicolas. Levothyrox® New and Old Formulations : Are they Switchable for Millions of Patients ? Clinical Pharmacokinetics. 2019 ;58:961-963.

Concordet D, Gandia P, Montastruc JL, Bousquet‑Mélou A, Lees P, Ferran AA, Toutain PL. Authors’ Reply to Castello‑Bridoux et al. Comment on Levothyrox® New and Old Formulations : Are they Switchable for Millions of Patients ? Clinical Pharmacokinetics. 2019 ;58:973-975.

Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran AA, Toutain PL. Authors’ Reply to Coste et al. “Levothyrox® New and Old Formulations : Are they Switchable for Millions of Patients ?” Clinical Pharmacokinetics. 2019 ;58:967-968.

Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran AA, Toutain PL. Author’s Reply to Trechot. Comment on Levothyrox® New and Old Formulations : Are they Switchable for Millions of Patients ? Clinical Pharmacokinetics. 2019 ;58:979-980.

Conte C, Vaysse C, Bosco P, Noize P, Fourrier-Reglat A, Despas F, Lapeyre-Mestre M. The value of a health insurance database to conduct pharmacoepidemiological studies in oncology. Therapie. 2019 ;74:279-288.

Conte C, Bourrel R, Despas F, Lapeyre-Mestre M. Is there overuse of proton pump inhibitors in B-cell non-Hodgkin lymphomas ? A cohort study based on the French health insurance database in the Midi-Pyrénées region. Fundam Clin Pharmacol. 2019 ;33:327-338.

Crickx E, Poullot E, Moulis G, Goulabchand R, Fieschi C, Galicier L, Meignin V, Coppo P, Delarue R, Casasnovas O, Roos-Weil D, de Leval L, Parrens M, Michel M, Dupuis J, Le Bras F, Fataccioli V, Martin-Garcia N, Godeau B, Haïoun C, Gaulard P, Mahévas M. Clinical spectrum, evolution, and management of autoimmune cytopenias associated with angioimmunoblastic T-cell lymphoma. Eur J Haematol. 2019 ;103:35-42.

Dardonville Q, Salguiero E, Rousseau V, Chebane L, Faillie JL, Gautier S, Montastruc JL, Carvajal A, Bagheri H. Drug-induced osteoporosis/osteomalacia : analysis in the French and Spanish pharmacovigilance databases. Eur J Clin Pharmacol. 2019 ;75:1705-1711.

De Barros S, Vayr F, Despas F, Strumia M, Podevin C, Gauthier M, Delabesse E, Soulat JM, Laurent G, Huguet F, Herin F. The impact of chronic myeloid leukemia on employment : the French prospective study. Ann Hematol. 2019 ;98:615-623.

De Germay S, Rueter M, Montastruc F, Rousseau V, Lapeyre-Mestre M, Montastruc JL. Trends of atropinic (anticholinergic) exposure in the elderly : a 10-year analysis in the French EGB database. Fundam Clin Pharmacol. 2019 ;33:471-478.

Despas F, Rousseau V, Lafaurie M, De Canecaude C, Durrieu G, Bagheri H, Montastruc F, Montastruc JL. Are lipid-lowering drugs associated with a risk of cataract ? A pharmacovigilance study. Fundam Clin Pharmacol. 2019:33 ;695-702.

Durrieu G, Dardonville Q, Clanet M, Montastruc JL. Cervical dysplasia in a patient with multiple sclerosis treated with natalizumab. Fundam Clin Pharmacol. 2019 ;33:125-126.

Favrelière S, Lafay-Chebassier C, Fauconneau B, Quillet A, Yéléhé-Okouma M, Montastruc F, Pérault-Pochat MC. Illogical association nalmefene and opioids : Analysis in the French pharmacovigilance database.Therapie. 2019 ;79:365-374.

Floyd JS, Bloch KM, Brody JA, Maroteau C, Siddiqui MK, Gregory R, Carr DF, Molokhia M, Liu X, Bis JC, Ahmed A, Liu X, Hallberg P, Yue QY, Magnusson PKE, Brisson D, Wiggins KL, Morrison AC, Khoury E, McKeigue P, Stricker BH, Lapeyre-Mestre M, Heckbert SR, Gallagher AM, Chinoy H, Gibbs RA, Bondon-Guitton E, Tracy R, Boerwinkle E, Gaudet D, Conforti A, van Staa T, Sitlani CM, Rice KM, Maitland-van der Zee AH, Wadelius M, Morris AP, Pirmohamed M, Palmer CAN, Psaty BM, Alfirevic A ; PREDICTION-ADR Consortium and EUDRAGENE. Pharmacogenomics of statin-related myopathy : Meta-analysis of rare variants from whole-exome sequencing. PLoS One. 2019 ;14:e0218115.

Humbert X, Fedrizzi S, Chrétien B, Sassier M, Bagheri H, Combret S, Drici MD, Le Bas F, Puddu PE, Alexandre J. Hypertension induced by serotonin reuptake inhibitors : Analysis of two pharmacovigilance databases. Fundam Clin Pharmacol. 2019 ;33:296-302.

Hurault-Delarue C, Morris JK, Charlton R, Gini R, Loane M, Pierini A, Puccini A, Neville A, Snowball J, Damase-Michel C ; EUROmediSAFE consortium. Prescription of antiepileptic medicines including valproate in pregnant women : A study in three European countries. Pharmacoepidemiol Drug Saf. 2019 ;28:1510-1518.

Hurault-Delarue C, Lacroix I, Bénard-Laribière A, Montastruc JL, Pariente A, Damase-Michel C. Antidepressants during pregnancy : a French drug utilisation study in EFEMERIS cohort. Eur Arch Psychiatry Clin Neurosci. 2019 ;841-849.

Kaguelidou F, Durrieu G, Clavenna A. Pharmacoepidemiological research for the development and evaluation of drugs in pediatrics. Therapie. 2019 ;74:315-324.

Koffi KG, Silué DA, Laurent C, Boidy K, Koui S, Compaci G, Adeba ZH, Kamara I, Botty RP, Bognini AS, Sanogo I, Despas F, Laurent G. AMAFRICA, a patient-navigator program for accompanying lymphoma patients during chemotherapy in Ivory Coast : a prospective randomized study. BMC Cancer. 2019 ;19:1247.

Lacroix C, Kheloufi F, Montastruc F, Bennis Y, Pizzoglio V, Micallef J. Serious central nervous system side effects of cephalosporins : A national analysis of serious reports registered in the French Pharmacovigilance Database. J Neurol Sci. 2019 ;398:196-201.

Lafaurie M, Montastruc F. Interest of a pharmacovigilance medical consultation : Example of metformin-induced-vitamin B12 deficiency. Presse Med. 2019 ;48:1216-1221.

Lapeyre-Mestre M, Montastruc F. Interest of pharmacoepidemiology for pharmacodynamics and analysis of the mechanism of action of drugs. Thérapie. 2019 ;74:209-2014.

Mines ML, Pacheco T, Castel-Lacana E, de Boissezon X, Marque P, Montastruc F. Venous thrombosis after botulinum therapy in lower limb : A case report and literature review. Ann Phys Rehabil Med. 2019 ;62:457-458.

Montastruc F, Nie R, Loo S, Rej S, Dell’Aniello S, Micallef J, Suissa S, Renoux C. Association of Aripiprazole With the Risk for Psychiatric Hospitalization, Self-harm, or Suicide. JAMA Psychiatry. 2019 ;76:409-417.

Montastruc F, Benevent J, Rousseau V, Durrieu G, Sommet A, Montastruc JL. Risk of Diabetes with Fibrates and Statins : a pharmacoepidemiological study in Vigibase®. Fundam Clin Pharmacol. 2018 ;33:108-112.

Montastruc F, Renoux C, Dell’Aniello S, Simon TA, Azoulay L, Hudson M, Suissa S. Abatacept initiation in rheumatoid arthritis and the risk of cancer : a population-based comparative cohort study. Rheumatology (Oxford). 2019 ;48:1053-1058.

Montastruc F, Khosrow-Khavar F, Sommet A, Renoux C, Montastruc JL. Tamoxifen administration and the risk of Parkinsonism. Eur J Clin Pharmacol. 2019 ;75:135-136.

Montastruc JL, Benevent J, Montastruc F, Bagheri H, Despas F, Lapeyre-Mestre M, Sommet A. What is pharmacoepidemiology ? Definition, methods, interest and clinical applications. Therapie. 2019 ;74:169-174.

Montastruc Jl, Montastruc F, Benevent J, Durrieu G, du Plantier JM, Bagheri H, Sommet A, Damase-Michel C. Tintin in the land of drugs : a pharmacological, pharmacovigilance approach. Therapie. 2019 ; 74:445-447.

Mouly S, Roustit M, Bagheri H, Perault-Pochat MC, Molimard M, Bordet R. The French Levothyrox® crisis : We did the best we could but…. Therapie. 2019 ;74:431-435.

Nguyen KD, Nguyen HA, Vu DH, Le TT, Nguyen HA Jr, Dang BV, Nguyen TN, Nguyen DH, Nguyen TB, Montastruc JL, Bagheri H. Drug-Induced Anaphylaxis in a Vietnamese Pharmacovigilance Database : Trends and Specific Signals from a Disproportionality Analysis. Drug Saf. 2018 ;42:671-682.

Nguyen KD, Tran TN, Nguyen MT, Nguyen HA, Nguyen HA Jr, Vu DH, Nguyen VD, Bagheri H. Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in vietnamese spontaneous adverse drug reaction database : A subgroup approach to disproportionality analysis. J Clin Pharm Ther. 2019 ;44:69-77.

Nicol C, Moulis F, Bondon-Guitton E, Durrieu G, Montastruc JL, Bagheri H. Does spontaneous adverse drug reactions’ reporting differ between different reporters ? A study in Toulouse Pharmacovigilance Centre. Therapie. 2019 ;5:521-525.

Petitpain N, Devos D, Bagheri H, Rocher F, Gouraud A, Masmoudi K, Coquerel A. Is TNF inhibitor exposure a risk factor foramyotrophic lateral sclerosis ? Fundam Clin Pharmacol. 2019 ;33:689-694.

Peyro-Saint-Paul L, Besnier P, Demessine L, Biour M, Hillaire-Buys D, de Canecaude C, Fedrizzi S, Parienti JJ. Cushing’s syndrome due to interaction between ritonavir or cobicistat and corticosteroids : a case-control study in the French Pharmacovigilance Database. J Antimicrob Chemother. 2019 ;74:3291-3294.

Sabatier P, Amar J, Montastruc F, Rousseau V, Chebane L, Bouhanick B, Montastruc JL. Breast cancer and spironolactone : an observational postmarketing study. Eur J Clin Pharmacol. 2019 ;75:1593-98.

Sommet A. Interest of pharmacoepidemiology for the study of antibiotic drugs. Therapie. 2019 ;74:249-253.

Sommet A, Pariente A. Methods in pharmacoepidemiology. Therapie. 2019 ;74:187-197.

Sommet A, Bénévent J, Rousseau V, Chebane L, Douros A, Montastruc JL, Montastruc F. What Fluoroquinolones Have the Highest Risk of Aortic Aneurysm ? A Case/Non-case Study in VigiBase®. J Gen Intern Med. 2019 ;34:502-503.

Tournier M, Montastruc F. Interest of pharmacoepidemiology for the study of psychotropic drugs. Therapie. 2019 ;74:239-244.

Tranchard F, Gauthier J, Hein C, Lacombe J, Brett K, Villars H, Sallerin B, Montastruc JL, Despas F. Drug identification by the patient : Perception of patients, physicians and pharmacists.Therapie. 2019 ;74:591-598.

Truffert E, Fournier Charrière E, Treluyer JM, Blanchet C, Cohen R, Gardini B, Haas H, Liard F, Montastruc JL, Nicollas R, Pondaven S, Stahl JP, Wood C, Couloigner V. Guidelines of the French Society of Otorhinolaryngology (SFORL) : Nonsteroidal anti-inflammatory drugs (NSAIDs) and pediatric ENT infections. Short version. Eur Ann Otorhinolaryngol Head Neck Dis. 2019 ;136:289-294.

Watson S, Durrieu G. Midostaurin, photosensitivity reaction. WHO U M C, 2019:1-7.

Ysebaert L, Larcher M, Compaci G, Oberic L, Sahnes L, Banos A, Araujo C, Sommet A, Laurent G, Despas F. Oncology nurse phone calls halve the risk of reduced dose intensity of immunochemotherapy : results of the randomized FORTIS study in chronic lymphocytic leukemia. Ann Hematol. 2019 ;98:931-939.